JetEquities

argenx Announces Positive Topline Results from Phase 3 ADAPT Tri

Long
NASDAQ:ARGX   argenx SE
ARGX: argenx SE
2020-05-26 01:00:00
argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis